In an early clinical trial , a single dose of a short-acting psychedelic drug led to rapid improvement in people with major depressive disorder. The study included 34 patients with moderate-to-severe depression , all of whom had tried other treatments without success. Those given a single intravenous dose of dimethyltryptamine (DMT) showed significant improvement within a week compared to those who received a placebo . Unlike psilocybin and lysergic acid diethylamide ( LSD ), whose effects can